Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association

Breast. 2018 Jun:39:150-151. doi: 10.1016/j.breast.2018.02.030. Epub 2018 Mar 9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Body Mass Index
  • Breast Neoplasms*
  • Humans
  • Receptor, ErbB-2
  • Trastuzumab*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab